Statin Therapy for Patients with Cardiovascular Disease (SPC)

Performance Measure Set: ☐ CCO Incentive Metric ☒ Medicare Star Measure Quality
Measurement Type: ☐ Structure ☒ Process ☐ Outcome ☐ Patient Experience
Data Type: ☒ Claims ☒ Chart Documentation ☐ eCQM ☐ Survey ☐ Other
HEDIS Benchmarks National Percentile: 83.94% (75th), 86.81% (90th)

**Who:** Female patients between 40–75 years of age and male patients between 21–75 years of age during the measurement period who have been identified as having clinical atherosclerotic cardiovascular disease.

**Why:** Cardiovascular disease is the leading cause of death in the United States. It is estimated that 92.1 million American adults have one or more types of cardiovascular disease. People with diabetes also have elevated cardiovascular risk, thought to be due in part to elevations in unhealthy cholesterol levels. Having unhealthy cholesterol levels places people at significant risk for developing ASCVD.

**What:** Percent of female members between 40–75 years of age and male members between 21–75 years of age who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and had at least one medication dispensing event for a high-intensity or moderate-intensity statin during the measurement period.

**How:** The denominator is the number of patients that have either a qualifying event (MI, CABG, PCI, other revascularization) in the year prior to the measurement year, or diagnosis of ischemic vascular disease (ICD) with a qualifying visit in both the measurement year and prior year. The numerator is the number of patients who had at least one dispensing event for a high- or moderate-intensity statin medication (listed in table below) during the measurement year.

**Exclusions:** Female patients with a diagnosis of pregnancy during the measurement year or year prior. All patients with ESRD or cirrhosis during the measurement year or year prior, myalgia, myositis, myopathy or rhabdomyolysis during the measurement year. Patients 66 years of age and older enrolled in an Institutional SNP or living in a long-term institution during the measurement year. Patients 66 years of age and older diagnosed with frailty and advanced illness during the measurement year or the year prior. Patients in hospice or palliative care are also excluded.

**High-intensity and Moderate-intensity Statin Medications:**

<table>
<thead>
<tr>
<th>High-intensity statin therapy</th>
<th>Atorvastatin 40-80 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amlodipine-atorvastatin 40-80 mg</td>
</tr>
<tr>
<td></td>
<td>Rosuvastatin 20-40 mg</td>
</tr>
<tr>
<td></td>
<td>Simvastatin 80 mg</td>
</tr>
<tr>
<td></td>
<td>Ezetimibe-simvastatin 80 mg</td>
</tr>
</tbody>
</table>
| Moderate-intensity statin therapy | Atorvastatin 10-20 mg  
Amlodipine-atorvastatin 10-20 mg  
Rosuvastatin 5-10 mg  
Simvastatin 20-40 mg  
Ezetimibe-simvastatin 20-40 mg  
Pravastatin 40-80 mg  
Lovastatin 40 mg  
Fluvastatin 40-80 mg  
Pitavastatin 2–4 mg |